DP
ENTX icon

Diadema Partners’s Entera Bio ENTX Stock Holding History

Diadema Partners’s Portfolio ENTX Stock Details ENTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25.8K Buy
+23,260
New +$32.6K ﹤0.01% 136

Other funds holding ENTX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SFCM
Seven Fleet Capital Management Mountain View, California $318M AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
SEIA
Signature Estate & Investment Advisors Los Angeles, California $5.56B AUM 26.66% 1-Year Est. Return

Diadema Partners's ENTX Position: Q1 2026 in Review

Diadema Partners opened a new position in Entera Bio (ENTX) in Q1 2026: 23,260 shares worth $25.8K. The stake represents ﹤0.01% of the portfolio and ranks #136 among its holdings.

26 funds tracked by Wall St. Rank hold ENTX as of Q1 2026.

  • Diadema Partners held 23,260 shares of Entera Bio worth $25.8K as of Q1 2026.
  • Entera Bio was a new Diadema Partners position in Q1 2026.
  • Entera Bio made up ﹤0.01% of Diadema Partners's portfolio in Q1 2026, its #136 holding.
  • 26 funds tracked by Wall St. Rank held Entera Bio as of Q1 2026.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.